✦ LIBER ✦

Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome

✍ Scribed by Yishay Ofran; Irit Avivi; Benjamin Gesundheit; Reuven Or; Jacob M. Rowe; Tsila Zuckerman

Book ID: 101439358
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 312 KB
Volume: 82
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.20773

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Arsenic trioxide as a treatment for myel

Arsenic trioxide as a treatment for myelodysplastic syndrome

✍ Mikkael A Sekeres 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 209 KB

Acute lung injury induced by arsenic tri

Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome

✍ Hesham A. Hassaballa; Omar B. Lateef; Michael R. Silver; Robert A. Balk 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 119 KB

Opportunities for Trisenox® (arsenic tri

Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes

✍ List, A; Beran, M; DiPersio, J; Slack, J; Vey, N; Rosenfeld, C S; Greenberg, P 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 202 KB

Combination decitabine, arsenic trioxide

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study

✍ John S. Welch; Jeffery M. Klco; Feng Gao; Elizabeth Procknow; Geoffery L. Uy; Ke 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 774 KB

Childhood immune thrombocytopenia (ITP) has a favorable outcome in most cases but severe bleeding may occur, mostly in children with very low platelet counts. Although first-line therapies are well defined, management of refractory ITP is not consensual. Vinblastine (VBL) is one second-line treatmen

Double minute chromosomes and c-MYC ampl

Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia

✍ Mathew, S; Lorsbach, R B; Shearer, P; Sandlund, J T; Raimondi, S C 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 274 KB

Maintenance treatment with azacytidine f

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy

✍ Michael Grövdal; Mohsen Karimi; Rasheed Khan; Anni Aggerholm; Petar Antunovic; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB